JHG vs. SEIC: Which Stock Should Value Investors Buy Now?
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Currently, both Janus Henderson Group plc and SEI Investments are holding a Zacks Rank of #2 (Buy). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that these stocks have improving earnings outlooks. But this is only part of the picture for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
JHG currently has a forward P/E ratio of 11.50, while SEIC has a forward P/E of 19.08. We also note that JHG has a PEG ratio of 1.36. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. SEIC currently has a PEG ratio of 1.59.
Another notable valuation metric for JHG is its P/B ratio of 1.27. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, SEIC has a P/B of 4.95.
These metrics, and several others, help JHG earn a Value grade of B, while SEIC has been given a Value grade of C.
Both JHG and SEIC are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that JHG is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Janus Henderson Group plc (JHG) : Free Stock Analysis Report
SEI Investments Company (SEIC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
VICI Properties Inc. (VICI) Q2 FFO Match Estimates
VICI Properties Inc. (VICI) came out with quarterly funds from operations (FFO) of $0.6 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.57 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post FFO of $0.58 per share when it actually produced FFO of $0.58, delivering no surprise. Over the last four quarters, the company has surpassed consensus FFO estimates just once. VICI Properties, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $1 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $957 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call. VICI Properties shares have added about 12.5% since the beginning of the year versus the S&P 500's gain of 8.3%. What's Next for VICI Properties? While VICI Properties has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions. Ahead of this earnings release, the estimate revisions trend for VICI Properties was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.60 on $997.1 million in revenues for the coming quarter and $2.38 on $3.99 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. SBA Communications (SBAC), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 4. This communications tower operator is expected to post quarterly earnings of $3.12 per share in its upcoming report, which represents a year-over-year change of -5.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. SBA Communications' revenues are expected to be $670.06 million, up 1.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report VICI Properties Inc. (VICI) : Free Stock Analysis Report SBA Communications Corporation (SBAC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 hours ago
- Yahoo
UDR (UDR) Beats Q2 FFO and Revenue Estimates
UDR (UDR) came out with quarterly funds from operations (FFO) of $0.64 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to FFO of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an FFO surprise of +3.23%. A quarter ago, it was expected that this real estate investment trust would post FFO of $0.61 per share when it actually produced FFO of $0.61, delivering no surprise. Over the last four quarters, the company has surpassed consensus FFO estimates just once. UDR, which belongs to the Zacks REIT and Equity Trust - Residential industry, posted revenues of $423 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.18%. This compares to year-ago revenues of $413.33 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call. UDR shares have lost about 6.5% since the beginning of the year versus the S&P 500's gain of 8.3%. What's Next for UDR? While UDR has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions. Ahead of this earnings release, the estimate revisions trend for UDR was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.63 on $426.95 million in revenues for the coming quarter and $2.50 on $1.7 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Residential is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Armada Hoffler Properties (AHH), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 4. This real estate company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -23.5%. The consensus EPS estimate for the quarter has been revised 1.3% higher over the last 30 days to the current level. Armada Hoffler Properties' revenues are expected to be $63.91 million, up 1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Dominion Realty Trust, Inc. (UDR) : Free Stock Analysis Report Armada Hoffler Properties, Inc. (AHH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.06 per share when it actually produced earnings of $0.06, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates two times. MiMedx, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $98.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 10.45%. This compares to year-ago revenues of $87.21 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. MiMedx shares have lost about 30.7% since the beginning of the year versus the S&P 500's gain of 8.3%. What's Next for MiMedx? While MiMedx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for MiMedx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.07 on $94.78 million in revenues for the coming quarter and $0.26 on $375.01 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Editas Medicine (EDIT), is yet to report results for the quarter ended June 2025. This genome editing company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Editas Medicine's revenues are expected to be $0.85 million, up 66.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MiMedx Group, Inc (MDXG) : Free Stock Analysis Report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
